Remove 2019 Remove Documentation Remove Packaging
article thumbnail

Beyond instruments: streamlining process technology implementation in biopharmaceutical manufacturing

European Pharmaceutical Review

Given that multiple work packages may often start or end together, or else take longer than others ( Figure 1 ), the introduction of new PAT requires assessment and planning by multiple departments. Any documentation, such as validation reports then helps with compliance and later regulatory submissions and requests.

article thumbnail

Navigating the regulatory challenge of PFAS for pharmaceutical manufacturers

European Pharmaceutical Review

billion Global concerns surrounding PFAS, or per- and polyfluoroalkyl substances, are due to their well-documented effects on human health and the environment. However, given that PFAS are ubiquitous in the environment from stain-resistant carpets and non-stick pans, to packaging and electronics, to name a few the task is not that simple.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Deviation investigation guidelines in the pharmaceutical industry

GMPSOP

Additional documents included each month. In the five years between 2019 and 2023, the FDA issued the following warning letters, closely related to ineffective deviation investigation. Packaging/labeling/Misbranding: 41 warnings vi. Additional documents included each month. All written and updated by GMP experts.

article thumbnail

Mastering Responses to FDA 510(k) AI Letters: A Strategic Approach

FDA Law Blog: Biosimilars

Performance Metric FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 Average Number of FDA Days to MDUFA IV Decision 72.62 In this case, the FDA clock start date is determined as the date of receiving the submission by the Document Control Center (DCC). Attachment number) and document name or description as appropriate.

article thumbnail

MSD secures full approval for Keytruda’s use in MSI-high solid tumours

Pharmaceutical Technology

There, the FDA suggested that the drugs undergo randomised controlled trials, which the document describes as the preferred approach, rather than single-arm trials. While the drug was granted accelerated approval in June 2019, it did not deliver on a key overall survival (OS) endpoint as part of its post-marketing data package.

article thumbnail

Driving Provider Value for Specialty Pharmacies

National Association of Boards of Pharmacy

Launched in 2019, NABP’s Specialty Pharmacy Accreditation was created to accredit pharmacies providing advanced levels of pharmacy services and disease management tools for patients taking medications that require special handling, storage, and dispensing requirements.

article thumbnail

Embracing green innovation in life sciences

European Pharmaceutical Review

5 However, the benefits are well documented. Sustainable pharma packaging: breaking down the barriers to adoption Over two years it resulted in approximately 52,000 inhalers being returned, equating to approximately 305 tonnes of CO 2. Pulmonary Pharmacology & Therapeutics. 2024; 85: 1-9. Internet] The Aerosol Society.